Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Cash & Equivalents (2020 - 2026)

Journey Medical filings provide 6 years of Cash & Equivalents readings, the most recent being $24.1 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 18.64% to $24.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.1 million, a 18.64% increase, with the full-year FY2025 number at $24.1 million, up 18.64% from a year prior.
  • Cash & Equivalents hit $24.1 million in Q4 2025 for Journey Medical, down from $24.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $49.1 million in Q4 2021 to a low of $8.2 million in Q2 2023.
  • Median Cash & Equivalents over the past 5 years was $24.1 million (2024), compared with a mean of $26.4 million.
  • Biggest five-year swings in Cash & Equivalents: soared 495.21% in 2021 and later tumbled 78.48% in 2023.
  • Journey Medical's Cash & Equivalents stood at $49.1 million in 2021, then tumbled by 34.8% to $32.0 million in 2022, then dropped by 14.37% to $27.4 million in 2023, then dropped by 25.89% to $20.3 million in 2024, then increased by 18.64% to $24.1 million in 2025.
  • The last three reported values for Cash & Equivalents were $24.1 million (Q4 2025), $24.9 million (Q3 2025), and $20.3 million (Q2 2025) per Business Quant data.